Genetic Therapies for Retinitis Pigmentosa: Current Breakthroughs and Future Directions

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Retinitis pigmentosa (RP) is a group of inherited retinal diseases causing progressive vision loss due to photoreceptor cell death.
• RP affects ~1 in 4000 individuals globally and is genetically heterogeneous, involving mutations in genes like RHO, PRPF31, RPE65, USH2A, and NR2E3.
• Current management focuses on symptom control, with a growing need for targeted therapies.

Purpose of the Study:

• To review the genetic underpinnings of retinitis pigmentosa.
• To explore emerging gene-based and other advanced therapeutic strategies for RP.
• To highlight the shift towards precision medicine in treating inherited retinal diseases.

Main Methods:

• Review of current literature on RP genetics and therapeutic development.
• Analysis of gene therapies (Luxturna, OCU400, QR-1123, SPVN06), optogenetic therapy (MCO-010), and genome editing (CRISPR-Cas).
• Discussion of clinical trial outcomes and preclinical findings.

Main Results:

• Luxturna is the first FDA-approved gene therapy for RPE65 mutations.
• OCU400 and SPVN06 offer gene-independent and mutation-agnostic approaches, respectively.
• QR-1123 shows promise for specific RHO mutations, while MCO-010 provides a pathway-independent treatment.
• CRISPR-Cas technology presents future potential for personalized mutation correction.

Conclusions:

• Significant advancements are being made in developing targeted therapies for retinitis pigmentosa.
• Innovative treatments like gene therapy, optogenetics, and genome editing are transforming RP management.
• The field is moving towards personalized, mutation-specific interventions for inherited retinal diseases, improving visual outcomes.